Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.03. | RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury | 47 | GlobeNewswire (Europe) | Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx"or the"Company"), focused on the discovery and development of innovative and... ► Artikel lesen | |
13.02. | RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine | 179 | GlobeNewswire (Europe) | Glen Rock, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and... ► Artikel lesen | |
02.02. | RespireRx Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.01. | RespireRx Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.01. | RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors | 1 | GlobeNewswire (USA) | ||
04.01. | RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient | 170 | GlobeNewswire (Europe) | Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and... ► Artikel lesen | |
11.12.23 | RespireRx Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.12.23 | RespireRX Pharmaceuticals Inc.: RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development | 191 | GlobeNewswire (Europe) | Glen Rock, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx" or the "Company"), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
17.11.23 | RespireRx Pharmaceuticals Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
14.11.23 | RespireRx Pharmaceuticals Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
12.10.23 | RespireRx, Ab Initio Partner on Dronabinol Manufacturing | 1 | Contract Pharma | ||
12.10.23 | RespireRx Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.10.23 | RespireRx Pharmaceuticals Inc.'s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services | 1 | GlobeNewswire (USA) | ||
02.10.23 | RespireRx Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.08.23 | RespireRX Pharmaceuticals Inc.: RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company | 212 | GlobeNewswire (Europe) | Glen Rock, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC. Pink Market: RSPI) ("RespireRx"), focused on the discovery and development of innovative and revolutionary treatments... ► Artikel lesen | |
24.05.23 | RespireRX Pharmaceuticals Inc.: ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs | 249 | GlobeNewswire (Europe) | Glen Rock, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx") and ResolutionRx Ltd ("ResolutionRx"), collectively "RespireRx" and its subsidiaries... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
DIGICANN VENTURES | 0,009 | +5,88 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 26.01.2024 | The following instruments on XETRA do have their first trading 26.01.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.01.2024
Aktien
1 KYG7006A1094 Perfect Corp.
2 JP3501950004... ► Artikel lesen | |
SANOCHEMIA PHARMAZEUTIKA | - | - | Nachlese: Magnus Brunner vs. FMA" EOSS holt nach Sanochemia auch BDI BioEnergy; Bettina Pfluger (Christian Drastil) | Um 12:12 liegt der ATX mit +0.03 Prozent im Plus bei 3452 Punkten (Ultimo 2023: 3435, 0.49% ytd). Topperformer der PIR-Group sind Addiko Bank mit +1.82% auf 15.425 Euro, dahinter DO&CO mit +1.79% auf... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,027 | -100,00 % | WPD Pharmaceuticals Inc: WPD Pharmaceuticals files 2021, 2022 results | ||
IONIS PHARMACEUTICALS | 41,180 | -0,10 % | Ionis reports positive results for rare disease treatment | ||
SINOPHARM | 2,363 | -2,44 % | CLSA Slightly Cuts SINOPHARM TP to $27, Rating Buy | ||
INDIVA | 0,035 | 0,00 % | Indiva Provides Corporate Update Including Improved Fourth Quarter Revenue Guidance | LONDON, Ontario--(BUSINESS WIRE)--Indiva Limited (the "Company" or "Indiva") (TSXV:NDVA), the leading Canadian producer of cannabis edibles, is pleased to provide a corporate update and recap of... ► Artikel lesen | |
CSPC PHARMA | 0,709 | -5,29 % | HSBC Research Cuts CSPC PHARMA TP to $7 as Innovative Projects on Track | ||
ORAMED PHARMACEUTICALS | 2,617 | +0,11 % | Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders | Initiating Phase 3 oral insulin trial in the United States under a new protocol
JV with Chinese Partner, HTIT
Scilex Senior Secured Note
PeriTech Asset Purchase & Strategic Out-licensing
NEW... ► Artikel lesen | |
ADASTRA | 0,134 | 0,00 % | Adastra Holdings Ltd.: Adastra Holdings Announces Record Total Purchase Orders Received in January and February | LANGLEY, BC / ACCESSWIRE / March 14, 2024 / Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian concentrates brands... ► Artikel lesen | |
ACADIA PHARMACEUTICALS | 16,800 | -0,59 % | Expert Ratings For ACADIA Pharmaceuticals | ||
SELLAS LIFE SCIENCES | 0,939 | -1,78 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study | - Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April - - Phase 2a study of SLS009 in r/r AML: 50% Response... ► Artikel lesen | |
METRIOPHARM | - | - | MetrioPharm erhält von FDA die Rare Pediatric Disease Designation (RPDD): Der Schweizer MetrioPharm ... | ||
MADRIGAL PHARMACEUTICALS | 240,00 | +0,08 % | Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock | ||
CATALYST PHARMACEUTICALS | 15,055 | +0,07 % | Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals | ||
NUMINUS WELLNESS | 0,068 | +5,08 % | Pharmala Biotech Holdings Inc: Pharmala Biotech to provide LaNeo MDMA to Numinus |